Phio Pharmaceuticals Corp.
PHIOAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 26, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 14, 2021 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2020 |
| HC Wainwright & Co. | maintain | Buy | Aug 5, 2020 |
| H.C. Wainwright | maintain | Buy | Jul 9, 2018 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.39| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.36 | $-0.36 | — | — |
| Aug 6, 2026 | $-0.36 | $-0.36 | — | — |
| May 7, 2026 | $-0.34 | $-0.24 | — | — |
| Mar 5, 2026 | $-0.15 | $-0.34 | — | — |
| Nov 13, 2025 | $-0.44 | $-0.45 | — | — |
| Aug 14, 2025 | $-0.45 | $-0.36 | — | — |
| May 15, 2025 | $-0.41 | — | — | — |
| Mar 31, 2025 | $-0.85 | $-1.23 | $70.0K | — |
News
INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherap…
PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDA King of Prussia, Pennsylvania--(Newsfile Corp. - November 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutic products based on its proprietary INTASYL® gene-silencing technology to eliminate cancer, today reported financia…
Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, in…
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing
Phio Pharmaceuticals (NASDAQ: PHIO) is advancing its lead immuno-oncology candidate, PH-762, as a potential neoadjuvant treatment for cutaneous squamous cell carcinoma, President and Chief Executive Officer Robert Bitterman said during a Virtual Investor Conferences presentation. The company's approach centers on INTASYL, a self-delivering short interfering RNA platform designed to silence specific genes. PH-762 targets PD-1, a
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile
Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking Associat…
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the …
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th…
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing